TeamDrive
RUS

Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

22 June 2015

June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

Full video is published at Vedomodsti web-site

According to Leonid Melamed, “The time of uncertainty is exactly the time when management should make important decisions both tactical and strategical that are usually postponed in other times or at least realized in a milder way. This is the right time to allocate internal resources aimed to ensure competitive advantages and to cut down the resources spent on the products, processes and areas that do not bring any competitive value in tactical viewpoint. Such periods are the time to reallocate strategic investments in something that will provide competitive value in 3 to 5 years when stability will come in place of uncertainty. Business model also must be changed, if necessary.

In other words, hard times create a welcomed opportunity for drastic changes that were difficult to realize under regular circumstances.”

In hard times, each business unit of the company is a key point. Such circumstances act as a rich soil to grow brilliant ideas and define the company’s future development. And only highly coordinated operation of all business units may lead the company to a success.

The Vedomosti’s FocusForum Conference will take place June 25, 2015, and bring together various experts who will share their ideas and valuable experience and try to identify an action plan for the future. General Managers, Heads of Business Development, HR, Marketing, Advertising and PR will introduce their business cases and strategies during panel discussions, presentations and unofficial personal meetings.

FocusForum web-site


Previous publication Next publication

Media Center

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

  • 18 October 2018

    Russia emerges as frontrunner in global fight against tuberculosis

    Russia has turned out to be the world’s most successful tuberculosis fighter, Russian Health Minister Veronika Skvortsova stated  during the interview with the Rossiya-24 channel. "We are the global leader according to the pace in solving this issue," she noted, adding, "all countries acknowledge Russia’s foremost role here."

  • 17 October 2018

    Scientists developed new tool for open exchange of biomaterials

    A new easy-to-use legal tool that enables open exchange of biological materials was launched. The OpenMTA is a Material Transfer Agreement (MTA) designed to support openness, sharing and innovation in global biotechnology. Material Transfer Agreements (MTAs) provide the legal frameworks within which research organisations define terms and conditions for sharing their materials – everything from DNA molecules to plant seeds to patient samples.

  • 16 October 2018

    The First FDA-approved Digital Pill — What It Means for Pharma

    Last year, the U.S. Food and Drug Administration (FDA) approved what is perhaps the boldest use of digital technology in healthcare: a pill that is integrated with an ingestible sensor that captures information about whether the patient has complied with her medication regimen. A patient ingests the pill and it sends the data to a patch worn on her torso, which adds various physiologic measures. From there the information is wirelessly sent to a mobile phone app, allowing both the patient and her physician to track how the patient is using and responding to her medication.

Read more